Estimate of maintenance EPO to darbepoetin alfa dose conversion ratio in a hospital-based dialysis patient population

References

• USRDS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD: United States Renal Data Systems, 2009
   Google Scholar
• Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989;35:134-48
   PubMed Web of Science ®Google Scholar
• Kazmi WH, Kausz AT, Khan S, et al. Anemia: an early complication of chronic renal insufficiency. Am J Kidney Dis 2001;38:803-12
   PubMed Web of Science ®Google Scholar
• Al-Ahmad A, Rand WM, Manjunath G, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Amer Coll Cardiol 2001;38:955-62
   PubMed Web of Science ®Google Scholar
• Astor BC, Coresh J, Heiss G, et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 2006;151:492-500
   PubMed Web of Science ®Google Scholar
• Ma JZ, Ebben J, Xia H, et al. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-19
   PubMed Web of Science ®Google Scholar
• McClellan WM, Flanders WD, Langston RD, et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002;13:1928-36
   PubMed Web of Science ®Google Scholar
• Xia H, Ebben J, Ma JZ, et al. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 1999;10:1309-16
   PubMed Web of Science ®Google Scholar
• Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ (Clinical research edn) 1990;300:573-8
   PubMedGoogle Scholar
• Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
   PubMed Web of Science ®Google Scholar
• Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006;45:503-10
   PubMed Web of Science ®Google Scholar
• Mahajan S, Boulton H, Gokal R. A trial of subcutaneous administration of darbepoetin alfa once every other week for the treatment of anemia in peritoneal dialysis patients. J Nephrol 2004;17:687-92
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167-75
   PubMed Web of Science ®Google Scholar
• Fang YW, Chang CH. Subcutaneous administration of darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals in peritoneal dialysis patients. Perit Dial Int 2009;29:199-203
   PubMed Web of Science ®Google Scholar
• Locatelli F, Canaud B, Giacardy F, et al. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003;18:362-9
   PubMed Web of Science ®Google Scholar
• Brunkhorst R, Bommer J, Braun J, et al. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients. Nephrol Dial Transplant 2004;19:1224-30
   PubMed Web of Science ®Google Scholar
• Locatelli F, Villa G, Backs W, et al. A phase 3, multicentre, randomized, double-blind, non-inferiority trial to evaluate the efficacy of Aranesp (darbepoetin alfa) once every 2 weeks (Q2W) vs Aranesp once weekly (QW) in patients on haemodialysis (HD). [abstract]. Nephrol Dial Transplant 2005;20(Suppl. 5):v260
   Google Scholar
• Nissenson AR. Dosing darbepoetin alfa. Am J Kidney Dis 2002;40:872
   PubMed Web of Science ®Google Scholar
• Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
   PubMed Web of Science ®Google Scholar
• Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002;22(9 PT 2):160S-5S
   PubMed Web of Science ®Google Scholar
• Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-18
   PubMed Web of Science ®Google Scholar
• Graf H, Lacombe J-L, Braun J, et al. Novel erythropoiesis stimulating protein (NESP) effectively maintains Hemoglobin (Hb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (r-HuEPO) in ESRD patients [abstract]. J Am Soc Nephrol 2000;11:A1317
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Barany P, Mann J. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin in ESRD patients when administered once weekly or once every other week [abstract]. J Am Soc Nephrol 1999;10:A1365
   Google Scholar
• Barron JJ, Grochulski WD, Mody SH, et al. Erythropoietic therapy: dosing patterns and calculated cost assessment for pre-dialysis chronic kidney disease patients in managed care setting. Pharm Ther 2007;32:661-70
   Google Scholar
• Bock HA, Hirt-Minkowski P, Brunisholz M, et al. Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008;23:301-8
   PubMed Web of Science ®Google Scholar
• Cremieux PY, Van Audenrode M, Lefebvre P. The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease. Curr Med Res Opin 2006;22:2329-36
   PubMed Web of Science ®Google Scholar
• Duh MS, Mody SH, McKenzie RS, et al. Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations. Drugs Aging 2006;23:969-76
   PubMed Web of Science ®Google Scholar
• Duh MS, Mody SH, Scott McKenzie R, et al. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clin Ther 2006;28:1443-50
   PubMed Web of Science ®Google Scholar
• Hirai T, Sugiya N, Nakashima A, et al. Switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients: dose conversion ratio. Nephron 2009;111:c81-6
   PubMed Web of Science ®Google Scholar
• Hymes J, Bickimer T, Jackson JH, et al. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Curr Med Res Opin 2007;23:1931-7
   PubMed Web of Science ®Google Scholar
• Laliberte F, Lefebvre P, Vekeman F, et al. Drug utilization and cost considerations of predialysis chronic kidney disease patients receiving erythropoiesis-stimulating agents through pharmacy benefits [abstract]. Am J Kidney Dis 2008;51:a25, no 130
   Web of Science ®Google Scholar
• Papatheofanis F, Smith C, Mody S, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study. Am J Ther 2007;14:322-7
   PubMedGoogle Scholar
• Papatheofanis FJ, McKenzie RS, Mody SH, et al. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin 2006;22:837-42
   PubMed Web of Science ®Google Scholar
• Raymond CB, Wazny LD, Vercaigne LM, et al. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios. CANNT J 2008;18:39-43
   PubMedGoogle Scholar
• Vekeman F, McKenzie RS, Lefebvre P, et al. Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. Am J Health Syst Pharm 2007;64:1943-9
   PubMed Web of Science ®Google Scholar
• CMS. End-Stage Renal Disease (ESRD) Payment Regulations and Notices. Available at: http://wwwcmshhsgov/ESRDPayment/PAY/itemdetailasp?filterType=none&filterByDID=-99&sortByDID=4&sortOrder=descending&itemID=CMS1228517&intNumPerPage=10 [Last accessed 13 October 2009]
   Google Scholar
• Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005;68:1337-43
   PubMed Web of Science ®Google Scholar
• Uehlinger DE, Gotch FA, Sheiner LB. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992;51:76-89
   PubMed Web of Science ®Google Scholar
• CMS. Rules and regulations. Fed Regist 2004;69:65796-7
   Google Scholar
• National Kidney Foundation. K/DOQI Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37(1 Suppl. 1):S182-238
   PubMed Web of Science ®Google Scholar
• Horowitz J, Agarwal A, Huang F, et al. Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease. J Manag Care Pharm 2009;15:741-50
   PubMed Web of Science ®Google Scholar